2025 CAP Congress / Congrès de l'ACP 2025

Session

(DPMB) T2-11 Neural Decay and Molecular Clues: Lipid Membranes, Amyloid, and Advanced Imaging Frontiers | Dégénérescence neuronale et indices moléculaires : membranes lipidiques, amyloïde et frontières de l'imagerie avancée (DPMB)

T2-11

10 Jun 2025, 14:15

Conveners

(DPMB) T2-11 Neural Decay and Molecular Clues: Lipid Membranes, Amyloid, and Advanced Imaging Frontiers | Dégénérescence neuronale et indices moléculaires : membranes lipidiques, amyloïde et frontières de l'imagerie avancée (DPMB)

• Dean Chapman (University of Saskatchewan)

424. Biophysics of neurodegeneration: molecular mechanisms of Alzheimer's disease, towards prevention and cure

Zoya Leonenko (Depts. of Physics & Astronomy and Biology, Waterloo Institute for Nanotechnology, U. Waterloo)

10/06/2025, 14:15

Physics in Medicine and Biology / Physique en médecine et en biologie (DPMB-DPMB)

Invited Speaker / Conférencier(ère) invité(e)

Alzheimer’s disease (AD) is a neurodegenerative disease characterized by dementia and memory loss for which no cure or prevention is available. Amyloid toxicity is a result of the non-specific interaction of toxic amyloid oligomers with the plasma membrane. We use biophysical approaches such as atomic force microscopy (AFM), Kelvin probe force
microscopy (KPFM), black lipid membrane (BLM) and...

293. Classification of Retinal TDP-43 and Amyloid beta Deposits as Biomarkers of Differing Neurodegenerative Diseases

Lyndsy Acheson (University of Waterloo)

10/06/2025, 14:45

Physics in Medicine and Biology / Physique en médecine et en biologie (DPMB-DPMB)

Oral Competition (Undergraduate Student) / Compétition orale (Étudiant(e) du 1er cycle)

Introduction: We have used polarized light to image and differentiate protein deposits as biomarkers of different neurodegenerative diseases and their severity; including amyloid deposits in Alzheimer’s disease (AD) and alpha synuclein deposits found in other brain diseases. Here we differentiate, with polarized light, retinal deposits of amyloid beta, associated with AD, from TDP-43...

421. The Aurora-RT – the Canadian Home-Grown Linac-MR Treatment Platform at the Cross Cancer Institute

Eugene Yip (Dept. of Oncology, University of Alberta)

10/06/2025, 15:00

Physics in Medicine and Biology / Physique en médecine et en biologie (DPMB-DPMB)

Invited Speaker / Conférencier(ère) invité(e)

Invented and developed at the Cross Cancer Institute in Edmonton, Alberta, the MagnetTx Aurora-RT is a made in Canada solution that combines a 6 MV linac producing therapeutic radiation and a biplanar 0.5 T MRI. This treatment platform received FDA clearance and treated its first patients recently. The primary benefit of such a device is to provide 3D MRI with excellent soft tissue contrast...